Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 8;5(1):71-86.
doi: 10.3390/neurosci5010005. eCollection 2024 Mar.

The Role of Astrocytes and Alpha-Synuclein in Parkinson's Disease: A Review

David Brash-Arias  1 , Luis I García  2 , César Antonio Pérez-Estudillo  2 , Fausto Rojas-Durán  2 , Gonzalo Emiliano Aranda-Abreu  2 , Deissy Herrera-Covarrubias  2 , Donaji Chi-Castañeda  2
Affiliations
Review

The Role of Astrocytes and Alpha-Synuclein in Parkinson's Disease: A Review

David Brash-Arias et al. NeuroSci. .

Abstract

The search for new therapies to reduce symptoms and find a cure for Parkinson's disease has focused attention on two key points: the accumulation of alpha-synuclein aggregates and astrocytes. The former is a hallmark of the disease, while the latter corresponds to a type of glial cell with an important role in both the prevention and development of this neurodegenerative disorder. Traditionally, research has focused on therapies targeting dopaminergic neurons. Currently, as more is known about the genetic and molecular factors and the neuroglial interaction in the disease, great emphasis has been placed on the neuroprotective role of astrocytes in the early stages of the disease and on the astrocytic capture of alpha-synuclein under both physiological and pathological conditions. This review aims to analyze the contribution of alpha-synuclein and astrocytes to the development and progression of Parkinson's disease, as well as to evaluate recent therapeutic proposals specifically focused on synucleopathies and astroglial cells as potential therapies for the disease.

Keywords: Parkinson’s disease; astrocytes; neurodegeneration; neurodegenerative disease; therapies; α-syn.

PubMed Disclaimer

Conflict of interest statement

Conflicts of InterestThe authors have no conflicts of interest to declare.

Similar articles

See all similar articles

References

    1. Parkinson J. An Essay on the Shaking Palsy. J. Neuropsychiatry Clin. Neurosci. 1817;14:223–236. doi: 10.1176/jnp.14.2.223. - DOI - PubMed
    1. Panicker N., Ge P., Dawson V.L., Dawson T.M. The cell biology of Parkinson’s disease. J. Cell Biol. 2021;220:e202012095. doi: 10.1083/jcb.202012095. - DOI - PMC - PubMed
    1. Bandres-Ciga S., Diez-Fairen M., Kim J.J., Singleton A.B. Genetics of Parkinson’s disease: An introspection of its journey towards precision medicine. Neurobiol. Dis. 2020;137:104782. doi: 10.1016/j.nbd.2020.104782. - DOI - PMC - PubMed
    1. Martínez-Ramírez D., Rodríguez-Violante M., Velázquez-Ávila E.S., Cervantes-Arriaga A., González-Cantú A., Corona T., Velásquez-Pérez L. Incidencia y distribución geográfica de la enfermedad de Parkinson en México. Salud Publica Mex. 2020;62:873–875. doi: 10.21149/11750. - DOI - PubMed
    1. Poewe W., Seppi K., Tanner C.M., Halliday G.M., Brundin P., Volkmann J., Schrag A.E., Lang A.E. Parkinson disease. Nat. Rev. Dis. Primers. 2017;3:1–21. doi: 10.1038/nrdp.2017.13. - DOI - PubMed

Grants and funding

D.B.-A. is supported by CONAHCYT-Mexico fellowship 510113.

LinkOut - more resources